No Data
No Data
Edgewise Therapeutics Price Target Maintained With a $48.00/Share by Piper Sandler
Piper Sandler Maintains Overweight on Edgewise Therapeutics, Maintains $48 Price Target
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $48
Piper Sandler analyst Yasmeen Rahimi maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 3
Edgewise Therapeutics (EWTX) Gets a Buy From Piper Sandler
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $31 Price Target
Edgewise Therapeutics Analyst Ratings